Leveraging Interactive Digital Technology to Increase Access to Family-Based Behavioral Treatment for Childhood Obesity (FBT 2)

September 23, 2026 updated by: 3-C Institute for Social Development

The primary goal of this SBIR Direct to Phase II is to expand upon the existing training platform to create an "all-in-one" digital product, FBT 2.0, that offers an integrated suite of intervention components, including (a) dynamic, personalized, self-paced program for children and parent/caregivers; (b) e-training and ongoing support for interventionists; and (c) family engagement and monitoring tools for interventionists. Investigators will create a comprehensive, e-learning digital intervention with engaging, interactive, and personalized online tools for youth and their parents/caregivers that are integrated into the broader interventionist platform.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Detailed Description

The primary goal of this SBIR Direct to Phase II is to expand upon the existing training platform to create an "all-in-one" digital product, FBT 2.0, that offers an integrated suite of intervention components, including (a) dynamic, personalized, self-paced program for children and parent/caregivers; (b) e-training and ongoing support for interventionists; and (c) family engagement and monitoring tools for interventionists. Investigators will create a comprehensive, e-learning digital intervention with engaging, interactive, and personalized online tools for youth and their parents/caregivers that are integrated into the broader interventionist platform. For the Pilot test , investigators will randomize enrolled caregiver-youth dyads (stratified by age group, i.e., 6 to 12, > 12) to one of three delayed-start cohorts with a 1-, 2-, or 3-month control period, after which all dyads receive FBT 2.0. Dyads assigned to receive FBT 2.0 will receive all eight modules over the 4-month treatment period, completing approximately one module every two weeks. Dyads will have free access to all completed modules for the duration of the treatment period, until the 6-month follow-up. Each module is expected to take approximately two to three sessions to complete, each session lasting approximately 45 minutes. At least one interventionist-led session (20-30 minutes) will occur per week, with additional sessions or coach support as needed via text exchange and/or videoconferencing supported on the website. Families will be able to engage with the software for as long as desired during the trial.

All caregiver-youth dyads receive the FBT 2.0 intervention. At enrollment, dyads are randomized to one of three delayed-start cohorts that begin treatment after a 1-, 2-, or 3-month control period. During the control period, dyads receive a link to American Academy of Pediatrics educational materials on healthy eating, physical activity, screen time, and sleep, and complete weight measurements; no treatment components are delivered. Prior to enrollment, dyads complete a 1-week run-in during which the caregiver and youth each log daily dietary intake using an online dietary tracking survey; dyads in which both members complete diary entries on at least 5 of 7 days are enrolled.

The same set of outcome measures will be collected for children and caregivers at four timepoints: (1) baseline (prior to randomization); (2) post-control (at the end of the assigned 1-, 2-, or 3-month control period); (3) post-treatment (after the 4-month intervention); and (4) at 2-month follow-up. Software usage data will be collected throughout the intervention period, and product evaluations will be collected at post-intervention.

Study Type

Interventional

Enrollment (Estimated)

66

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • North Carolina
      • Durham, North Carolina, United States, 27713
        • 3C Institute
        • Principal Investigator:
          • Melissa DeRosier, PhD
        • Contact:
          • Melissa DeRosier, PhD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

6 years and older (Child, Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • must be youth between the ages of 6 and 17
  • must have a body mass index (BMI) percentile greater than or equal to the 85th BMI percentile for age and sex
  • must have one caregiver participate, who is at least 18 years of age and lives with the child at least 50% of the time.
  • the participating caregiver must have a body mass index (BMI) of 25 or greater
  • youth and caregiver must be English proficient
  • family must have reliable internet access and a working scale in the home

Exclusion Criteria:

  • co-morbid disorders that contraindicate weight loss (e.g., eating disorder).
  • caregiver has a medical or psychiatric condition in which weight loss is contraindicated (e.g., pregnancy)
  • youth is unable to provide assent

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Sequential Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: FBT 2.0

Dyads assigned to receive FBT 2.0 will receive all eight modules over the 4-month treatment period, completing approximately one module every two weeks. Dyads will have free access to all completed modules for the duration of the treatment period Each module is expected to take approximately two to three sessions to complete, each session lasting approximately 45 minutes. At least one interventionist-led session (20-30 minutes) will occur per week, with additional sessions or coach support as needed via text exchange and/or videoconferencing supported on the website. Families will be able to engage with the software for as long as desired during the trial.

FBT 2.0 is a translation of Family-Based Behavioral Treatment (FBT) into an e-health intervention product for families with a child/adolescent with obesity. FBT is an evidence-based obesity intervention that takes a family-centered approach to weight management that includes training in behavioral skills for the family, such as self-monitoring, stimulus control, problem solving, pre-planning, and impulse control. Youth with obesity, along with one participating caregiver, will be introduced to the evidence- based Traffic Light Eating Plan and behavioral skill training appropriate for their developmental age, while the caregiver learns positive parenting approaches to help shape and support their child's weight change efforts in addition to their own weight management goals. The final product will consist of eight modules, each aligned with evidence-based FBT skills and competencies.

Other: Delayed-Start Control

All caregiver-youth dyads receive the FBT 2.0 intervention. At enrollment, dyads are randomized to one of three delayed-start cohorts that begin treatment after a 1-, 2-, or 3-month control period. During the control period, dyads receive a link to American Academy of Pediatrics educational materials on healthy eating, physical activity, screen time, and sleep, and complete weight measurements; no treatment components are delivered. Prior to enrollment, dyads complete a 1-week run-in during which the caregiver and youth each log daily dietary intake using an online dietary tracking survey; dyads in which both members complete diary entries on at least 5 of 7 days are enrolled.

All caregiver-youth dyads receive the FBT 2.0 intervention. At enrollment, dyads are randomized to one of three delayed-start cohorts that begin treatment after a 1-, 2-, or 3-month control period. During the control period, dyads receive a link to American Academy of Pediatrics educational materials on healthy eating, physical activity, screen time, and sleep, and complete weight measurements; no treatment components are delivered. Prior to enrollment, dyads complete a 1-week run-in during which the caregiver and youth each log daily dietary intake using an online dietary tracking survey; dyads in which both members complete diary entries on at least 5 of 7 days are enrolled.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Relative Weight
Time Frame: Baseline, post-control (1 to 3 months depending on Cohort), post-treatment (4 months), and 2-month follow-up (6 months)

Youth: The participating caregiver is given the CDC guidelines for "Measuring Children's Height and Weight Accurately at Home." The FBT coach will review these guidelines with the caregiver to assure comprehension. Median body mass index (BMI) for that child's age (in months) and sex is based on norms defined by Kuczmarski and colleagues and available from the CDC. Percent overweight was chosen as the primary outcome measure given its sensitivity to change throughout the BMI range. Caregiver: Exploratory analyses will examine caregiver weight change, defined as percent change from weight at baseline, among caregivers who have obesity (BMI ≥ 30) at baseline.

Baseline, post-control (1 to 3 months depending on Cohort), post-treatment (4 months), and 2-month follow-up (6 months)
Youth Pediatric Symptom Checklist-17
Time Frame: Baseline, post-control (1 to 3 months depending on Cohort), post-treatment (4 months), and 2-month follow-up (6 months)

Youth: The Pediatric Symptom Checklist-17 is a widely used, briefer version of the PSC-35, a caregiver-completed measure of children's psychosocial functioning, where caregivers rate each symptom on a scale of 0-2, where 0 means never, 1 means sometimes, and 2 means often.

Baseline, post-control (1 to 3 months depending on Cohort), post-treatment (4 months), and 2-month follow-up (6 months)
Youth Center for Epidemiological Studies Depression Scale for Children
Time Frame: Baseline, post-control (1 to 3 months depending on Cohort), post-treatment (4 months), and 2-month follow-up (6 months)

Youth: Depression is measured in children using a 20-item Center for Epidemiological Studies Depression Scale for Children. Possible scores range from 0-60 with each item response scored as 0 = Not At All, 1 = A Little, 2 = Some, and 3 = A Lot.

Baseline, post-control (1 to 3 months depending on Cohort), post-treatment (4 months), and 2-month follow-up (6 months)
Caregiver Adult Patient Health Questionnaire
Time Frame: Baseline, post-control (1 to 3 months depending on Cohort), post-treatment (4 months), and 2-month follow-up (6 months)

Caregiver: Adults complete the 2- item Patient Health Questionnaire to measure depression. Each symptom is scored on a scale of 0-3, with 0 = Not At All, 1 = Several Days, 2 = More than half the Days, and 3 = Nearly every day.

Baseline, post-control (1 to 3 months depending on Cohort), post-treatment (4 months), and 2-month follow-up (6 months)
Family Nutrition and Physical Activity Screening Tool
Time Frame: Baseline, post-control (1 to 3 months depending on Cohort), post-treatment (4 months), and 2-month follow-up (6 months)

The Family Nutrition & Physical Activity Screening Tool is a 20-item parent-report scale designed to assess family environments and practices that have been shown to be associated with children's risk of becoming overweight. Each item is scored on a 1-4 point scale with 4 representing the more favorable practice or policy.

Baseline, post-control (1 to 3 months depending on Cohort), post-treatment (4 months), and 2-month follow-up (6 months)
Caregiver Generalized Anxiety Disorder-7 (GAD-7)
Time Frame: Baseline, post-control (1 to 3 months depending on Cohort), post-treatment (4 months), and 2-month follow-up (6 months)

Caregiver: The GAD-7 is a 7-item measure of anxiety symptoms. Items are scored 0-3; total scores range 0-21, with higher scores indicating greater anxiety severity.

Baseline, post-control (1 to 3 months depending on Cohort), post-treatment (4 months), and 2-month follow-up (6 months)
Youth Screen for Child Anxiety Related Disorders (SCARED)
Time Frame: Baseline, post-control (1 to 3 months depending on Cohort), post-treatment (4 months), and 2-month follow-up (6 months)

Youth: The 5-item SCARED is a brief screening measure for child anxiety disorders. Items are scored 0-2; total scores range 0-10, with higher scores indicating greater anxiety and scores of 3 or higher indicating possible anxiety disorder.

Baseline, post-control (1 to 3 months depending on Cohort), post-treatment (4 months), and 2-month follow-up (6 months)
Caregiver Brief Eating Disorder Examination Questionnaire (EDE-Q Brief)
Time Frame: Baseline, post-control (1 to 3 months depending on Cohort), post-treatment (4 months), and 2-month follow-up (6 months)

Caregiver: The EDE-Q Brief is a brief self-report version of the Eating Disorder Examination Questionnaire assessing eating disorder psychopathology. Higher scores indicate greater eating disorder pathology.

Baseline, post-control (1 to 3 months depending on Cohort), post-treatment (4 months), and 2-month follow-up (6 months)
Youth Brief Eating Disorder Examination Questionnaire (Youth EDE-Q Brief)
Time Frame: Baseline, post-control (1 to 3 months depending on Cohort), post-treatment (4 months), and 2-month follow-up (6 months)

Youth: The Youth EDE-Q Brief (Body U) is a brief youth-report version of the Youth Eating Disorder Examination Questionnaire assessing eating disorder psychopathology. Higher scores indicate greater eating disorder pathology.

Baseline, post-control (1 to 3 months depending on Cohort), post-treatment (4 months), and 2-month follow-up (6 months)
Experiences of Weight Stigma
Time Frame: Baseline, post-control (1 to 3 months depending on Cohort), post-treatment (4 months), and 2-month follow-up (6 months)

Experiences of weight-based stigma will be assessed by self-report for caregivers and youth, with higher scores indicating more frequent experiences of weight stigma.

Baseline, post-control (1 to 3 months depending on Cohort), post-treatment (4 months), and 2-month follow-up (6 months)
Youth Experiences with Teasing and Bullying
Time Frame: Baseline, post-control (1 to 3 months depending on Cohort), post-treatment (4 months), and 2-month follow-up (6 months)

Youth: The Experiences with Teasing and Bullying measure is a 12-item youth-report tool evaluating experiences of teasing and bullying, administered verbally for children under age 8. Higher scores indicate more frequent experiences.

Baseline, post-control (1 to 3 months depending on Cohort), post-treatment (4 months), and 2-month follow-up (6 months)
Food Insecurity (Hunger Vital Sign)
Time Frame: Baseline, post-control (1 to 3 months depending on Cohort), post-treatment (4 months), and 2-month follow-up (6 months)

Caregiver: The Hunger Vital Sign is a validated 2-item food insecurity screener. An affirmative response to either item indicates risk of household food insecurity.

Baseline, post-control (1 to 3 months depending on Cohort), post-treatment (4 months), and 2-month follow-up (6 months)
Delay Discounting
Time Frame: Baseline, post-control (1 to 3 months depending on Cohort), post-treatment (4 months), and 2-month follow-up (6 months)

Youth and Caregiver: The Delay Discounting Task measures the tendency to discount the value of delayed rewards. Steeper discounting rates indicate greater preference for immediate rewards.

Baseline, post-control (1 to 3 months depending on Cohort), post-treatment (4 months), and 2-month follow-up (6 months)
Relative Reinforcing Efficacy of Food
Time Frame: Baseline, post-control (1 to 3 months depending on Cohort), post-treatment (4 months), and 2-month follow-up (6 months)

Youth and Caregiver: The relative reinforcing value of food is measured by questionnaire, with higher scores indicating greater reinforcing value of food relative to alternative activities.

Baseline, post-control (1 to 3 months depending on Cohort), post-treatment (4 months), and 2-month follow-up (6 months)
Automated Self-Administered 24-hour Dietary Assessment Tool
Time Frame: Baseline, post-control (1 to 3 months depending on Cohort), post-treatment (4 months), and 2-month follow-up (6 months)

The Automated Self-Administered 24-hour (ASA24®) Dietary Assessment Tool is a free, web-based tool that enables automatically coded, self-administered 24-hour diet recalls that will be completed by the participating adolescent aged 13 or older, or with the caregiver's assistance (for youth < 13 years of age). The caregiver will also complete a 24-hour dietary recall for their own intake. Outcomes will be average daily kilocalories, fruit and vegetable servings, and percentage intake from fat.

Baseline, post-control (1 to 3 months depending on Cohort), post-treatment (4 months), and 2-month follow-up (6 months)
Physical activity
Time Frame: 7 days at each assessment timepoint

Objective physical activity will be assessed for youth and caregivers using accelerometers worn on the wrist during sleep and daily activities for seven days at each assessment time point. Outcomes will be minutes of moderate or vigorous activity (physical activity) and minutes of sedentary activity.

7 days at each assessment timepoint
Caregiver PROMIS Global Health
Time Frame: Baseline, post-control (1 to 3 months depending on Cohort), post-treatment (4 months), and 2-month follow-up (6 months)

Caregiver: The PROMIS Global Health scale (v1.2) is a 10-item measure of overall physical and mental health-related quality of life. Items are scored on 5-point scales; raw scores are converted to T-scores, with higher scores indicating better health.

Baseline, post-control (1 to 3 months depending on Cohort), post-treatment (4 months), and 2-month follow-up (6 months)
Youth PROMIS Pediatric Global Health
Time Frame: Baseline, post-control (1 to 3 months depending on Cohort), post-treatment (4 months), and 2-month follow-up (6 months)

Youth: The PROMIS Pediatric Global Health 7+2 is a 9-item child-report measure of perceived physical, mental, and social health. Raw scores are converted to T-scores, with higher scores indicating better global health.

Baseline, post-control (1 to 3 months depending on Cohort), post-treatment (4 months), and 2-month follow-up (6 months)
Intervention Feedback
Time Frame: At completion of the 4-month intervention

Caregivers and youth in both conditions will provide feedback regarding their experiences during the trial period. On a 5-point scale (1=Strongly Disagree to 5=Strongly Agree), respondents will rate the degree to which their experience was: (a) useful for increasing knowledge of weight-related behaviors; (b) useful for learning self-management skills; (c) helped with changing unhealthy behaviors; (d) valuable for families and youth with obesity; (e) engaging for families; (f) innovative compared to alternatives; and (g) better than alternatives. Additionally, child and parent satisfaction with FBT will be assessed at the end of treatment using the 8-item Client Satisfaction Questionnaire. Participants will also be asked to provide written comments, listing specific concerns or problems. Follow-up interviews via telephone by trained research assistants will be conducted to clarify responses and gather additional details, as needed.

At completion of the 4-month intervention
Product Evaluation
Time Frame: At completion of the 4-month intervention

In addition, participants will rate (5-point scale from 1=Not at all to 5=Extremely) the quality of FBT 2.0 in the following areas: (a) user friendly; (b) easy to navigate; (c) appealing graphic design; (d) easy to follow directions; (e) jargon free; (f) engaging; (g) high quality content; (h) high value content; (i) relevance to real-life; (j) login functions; (k) search functions; and (l) help functions.

At completion of the 4-month intervention

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Collaborators

Investigators

  • Principal Investigator: Denise Wilfley, PhD, Washington University School of Medicine
  • Principal Investigator: Melissa DeRosier, PhD, 3C Institute
  • Principal Investigator: Leonard Epstein, PhD, University at Buffalo

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

October 1, 2026

Primary Completion (Estimated)

July 31, 2027

Study Completion (Estimated)

September 30, 2027

Study Registration Dates

First Submitted

December 6, 2024

First Submitted That Met QC Criteria

December 10, 2024

First Posted (Actual)

December 11, 2024

Study Record Updates

Last Update Posted (Actual)

September 28, 2026

Last Update Submitted That Met QC Criteria

September 23, 2026

Last Verified

September 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • FBT 2.0 DPII

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

Data generated by this project will be made available upon request after the publication of the main findings from each aim. Investigators will require parties requesting data access to submit a detailed description of their plans for the data with their personal identification, institutional affiliation, a CV, estimated duration of the proposed research, source of financial support, and a conflict-of-interest statement. The MPIs will decide whether sharing of the data is appropriate or if other information and/or additional safeguards are needed. Once the request is approved, data transfer and use agreements will be developed if necessary, and the requesting investigator must obtain approval from their institution's IRB or request to rely on the IRB of record. Appropriate de- identification techniques required by both HIPAA and the Common Rule will allow for sharing of data that does not compromise participant confidentiality.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.